BS_MT15SGJN
EPN · Supratentorial EPN
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- EPN
- cancer_type_detailed
- —
- subtype
- Supratentorial EPN
- cancer_type
- EPN
- subtype
- Supratentorial EPN
- overall_survival_months
- 67.92
- os_event
- true
- age_years
- 18.342
- sex
- M
- race
- White
- fusion
- ZFTA_RELA
- e1_e2
- E1
- umap1_2d
- -1.747330865
- umap2_2d
- 1.676967444
- umap1_3d
- -0.354186377
- umap2_3d
- 4.156755658
- umap3_3d
- -3.058992099
- dataset
- EPN-CBTN
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.560
- MYC_TARGETS_V1+0.540
- OXIDATIVE_PHOSPHORYLATION+0.490
- E2F_TARGETS+0.410
- INTERFERON_ALPHA_RESPONSE+0.390
- MTORC1_SIGNALING+0.390
- UNFOLDED_PROTEIN_RESPONSE+0.380
- INTERFERON_GAMMA_RESPONSE+0.360
- ALLOGRAFT_REJECTION+0.340
- ANDROGEN_RESPONSE+0.330
Top 10 suppressed
- KRAS_SIGNALING_DN-0.350
- MYOGENESIS-0.350
- APICAL_JUNCTION-0.270
- HYPOXIA-0.270
- APICAL_SURFACE-0.220
- HEDGEHOG_SIGNALING-0.170
- WNT_BETA_CATENIN_SIGNALING-0.160
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.140
- ESTROGEN_RESPONSE_EARLY-0.140
- TNFA_SIGNALING_VIA_NFKB-0.140
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_MT15SGJN | Supratentorial Ependymoma | — | 0.946 |
| 2 | BS_W80TJC27 | EPN | Supratentorial EPN | 0.920 |
| 3 | BS_CZ3ER8DY | EPN | Supratentorial EPN | 0.905 |
| 4 | SJEPD030367_D2.RNA-Seq | EPN | Supratentorial EPN | 0.898 |
| 5 | BS_W80TJC27 | Supratentorial Ependymoma | — | 0.897 |
| 6 | SJEPD030391_D1.RNA-Seq | EPN | Supratentorial EPN | 0.880 |
| 7 | 46E565A7-5022-4648-9035-B60FC7CFD6E7 | — | — | 0.879 |
| 8 | SJEPD030292_D1.RNA-Seq | EPN | Supratentorial EPN | 0.857 |
| 9 | SRR17866853 | — | — | 0.842 |
| 10 | MNG1200 | — | — | 0.842 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.560 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.540 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.490 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.410 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.390 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.390 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.380 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.360 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.340 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.330 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.320 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.320 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.290 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.290 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.290 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.230 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.190 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.170 | Idelalisib | — uncovered |
| APOPTOSIS | 0.160 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.160 | Idelalisib | — uncovered |